11β hsd1 in 1

11β-HSD1 inibitor 17 is an inhibitor of 11β-hydroxysteroid dehydrogenase (11β-HSD1).

11β-HSD1 inibitor 19 shows inhibitory activities for hHSD1 and mHSD1 with IC50s of 16 nM and 10 nM.

11β-HSD1-IN-12 is an 11β-HSD1 inhibitor.11β-HSD1-IN-12 is implicated in the conversion of glucocorticoids in vivo and can be used to study metabolic syndrome and obesity.

11β-HSD1-IN-1 is an inhibitor of 11β-hydroxydehydrogenase 1 (11β-HSD1, IC50: 52 nM) used for the treatment of pain.

AZD8329 is a selective and potent 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that inhibits 11β-HSD2, 17β-HSD1, 17β-HSD3, and can be used for the study of allergic reactions in humans.

BI-135585 is an orally active, selective and potent inhibitor of human 11β-hydroxysteroid dehydrogenase-1 (HSD1) for the study of type 2 diabetes.

11β-HSd1-in-11 is a potent and competitive inhibitor of 11-β-hydroxysteroid dehydrogenase 1 (11β-HSD1) IN rats and humans with IC50 values of 0.34 μM and 0.13 μM, respectively. 11β-Hsvd1-in-11 is a compound used as a chemical compound. 11β-HSD1-IN-11 is a hormone involved in regulating various physiological processes, such as metabolism, inflammation, and stress responses. 11β-Hd1-in-11 is a potential compound for the treatment of metabolic disorders, obesity, and certain inflammatory conditions.

HSD-016 is an orally active, selective and potent type 1 11β-hydroxysteroid dehydrogenase (11β-HSD1) inhibitor with strong inhibitory effects on human, mouse and rat 11β-HSD1.HSD-016 can be used in the study of diabetes and metabolic syndrome.

UE2343 is a brain-penetrant, orally active 11β-HSD1 inhibitor for Alzheimer's disease research.

SKI2852 is an orally active, selective, and efficient 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor, improving metabolic syndrome in diabetic mouse models.

INCB13739 is an orally active, selective, and highly efficient 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) inhibitor. INCB13739 improves hyperglycemia in patients with uncontrolled type 2 diabetes on metformin monotherapy and can be used in hyperlipidemia and hypertriglyceridemia research.

11β-HSD1-IN-6 is a potent inhibitor of 11β hydroxysteroid dehydrogenase enzymes (11β-HSDs), which catalyze the conversion of active glucocorticoids, corticosterone or cortisol, to their inactive forms, 11-dehydrocorticosterone (11-DHC) and cortisone. The compound specifically targets and inhibits 11β-HSD-1, modulating the interconversion of these glucocorticoids. [1]

KR-67607, also known as NTX-101 is novel selective 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) inhibitor. KR-67607 decreased 4-hydroxynonenal expression and increased antioxidant and mucus secretion in BAC-treated rat eyes. KR-67607 showed its protective effects against ischemia-reperfusion-induced eye injury. KR-67607 effectively reduced cortisol levels in mouse eyes and maintained the trabecular meshwork (TM) structure in the presence of transient ischemic stress. Furthermore, KR-67607 reversed the elevation of intra-ocular pressure (IOP), suggesting that the TM structure maintained by KR-67607 prevented the excessive rise in IOP that exacerbates glaucoma.

WAY-328127 is an active molecule, exhibiting an inhibitory effect on the (11β-hydroxysteroid dehydrogenase type 1) [(11β-HSD1)] enzyme. This modulation potentially leads to therapeutic applications in metabolic disorders, including (type 2 diabetes) [(T2D)] and metabolic syndrome. Its action in selectively downregulating (11β-HSD1) in adipose tissue suggests a favourable profile for addressing hyperglycemia and dyslipidemia.

JTT-654 is a potent and selective orally active inhibitor of 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1). It exhibits IC50 values of 4.65, 0.97, and 0.74 nM for human, rat, and mouse recombinant enzymes, respectively, and demonstrates competitive inhibition against the human recombinant enzyme. The IC50 value for human 11β-HSD2 is greater than 30 μM, as this enzyme is responsible for the reverse reaction against human 11β-HSD1. JTT-654 improves insulin resistance and non-obese type 2 diabetes by targeting 11β-HSD1 in adipose tissue and the liver [1] [2].